In This Story
Federal nutrition health policy often relies on broad, generalized recommendations that are not always applicable to individual differences, ultimately limiting the effectiveness of programs and personalized dietary guidance. A randomized clinical trial by Raedeh Basiri on continuous glucose monitoring (CGM) is cited in a 2025 letter addressed to the Commissioner of Food and Drugs at the U.S. Food and Drug Administration (FDA) Martin Makary. Basiri’s contributions in the letter support the need for widespread access to CGM technology, asserting its impact on individualized nutritional therapy success and ability to maintain optimal glucose levels among those at risk of type 2 diabetes.
“My hope is this work helps shape future policies that expand continuous glucose monitoring access to individuals at risk for diabetes, promote nutrition-driven prevention strategies, and encourage federal health agencies—from FDA to the Centers for Medicare & Medicaid Services —to adopt personalized, data-driven approaches that position nutrition as an actionable cornerstone of chronic disease prevention,” said Basiri, an assistant professor of nutrition and dietitian in the College of Public Health.
The letter was sent on behalf of The Time in Range Coalition, a diverse group of nutrition experts, nonprofit organizations, professional societies, and patient advocates working to drive awareness and adoption of diabetes prevention.
Basiri’s citation underscores the presence of George Mason University in shaping evidence-based policy development and approaches to chronic disease prevention.
CGM provides real-time feedback on blood glucose levels. Access to real-time feedback empowers individuals to sustain positive nutritional behavior change, supports adherence to dietary recommendations, and reduces anxiety about their ability to maintain glucose control.
Enhancing the Impact of Individualized Nutrition Therapy with Real-Time Continuous Glucose Monitoring Feedback in Overweight and Obese Individuals with Prediabetes, authored by Basiri and fellow nutrition Professor Lawrence Cheskin, provides evidence supporting the integration of personalized nutrition therapy enhanced by real-time CGM feedback into national diabetes prevention and management policy.